Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Friedman

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Neuropathology and Experimental Neurology|January 20, 2009
Hyaline protoplasmic astrocytopathy of neocortexE Tessa Hedley-Whyte, James E Goldman, Maiken Nedergaard, et al.
RMD Open|March 5, 2022
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension studyKevin Winthrop, Juan Ignacio Vargas, Edit Drescher, et al.
JCI Insight|January 28, 2021
The Na+, K+-ATPase β1 subunit regulates epithelial tight junctions via MRCKαHaiqing Bai, Rui Zhou, Michael Barravecchia, et al.
Urology|October 2, 2007
Extending the application of tubeless percutaneous nephrolithotomyMario Sofer, Avi Beri, Alan Friedman, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|October 24, 2008
Model curriculum for academic child and adolescent psychiatry trainingDorothy Stubbe, Andrés Martin, Michael Bloch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Neuropathology and Experimental Neurology|January 20, 2009
Hyaline protoplasmic astrocytopathy of neocortexE Tessa Hedley-Whyte, James E Goldman, Maiken Nedergaard, et al.
RMD Open|March 5, 2022
Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension studyKevin Winthrop, Juan Ignacio Vargas, Edit Drescher, et al.
JCI Insight|January 28, 2021
The Na+, K+-ATPase β1 subunit regulates epithelial tight junctions via MRCKαHaiqing Bai, Rui Zhou, Michael Barravecchia, et al.
Urology|October 2, 2007
Extending the application of tubeless percutaneous nephrolithotomyMario Sofer, Avi Beri, Alan Friedman, et al.
Arthritis Research & Therapy|December 4, 2019
Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugsVibeke Strand, Michael Schiff, Namita Tundia, et al.
Arthritis Research & Therapy|December 10, 2019
Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Arthritis Research & Therapy|June 11, 2020
Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXTVibeke Strand, Janet Pope, Namita Tundia, et al.
Academic Psychiatry : the Journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry|October 24, 2008
Model curriculum for academic child and adolescent psychiatry trainingDorothy Stubbe, Andrés Martin, Michael Bloch, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2016
A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor TherapyJoel M Kremer, Paul Emery, Heidi S Camp, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 9, 2020
Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled TrialRonald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, et al.
Pageof 6